Bromfenac ophthalmic - InSite Vision

Drug Profile

Bromfenac ophthalmic - InSite Vision

Alternative Names: Bromfenac ophthalmic 0.075%; BromSite; ISV-101; ISV-303

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InSite Vision; Sun Pharmaceutical Industries
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • Phase I/II Dry eyes
  • Research Retinal oedema

Most Recent Events

  • 08 Sep 2017 InSite Vision plans a phase II trial of bromfenac ophthalmic for Dry eye disease in 2018 (NCT01478555)
  • 28 Aug 2017 InSite Vision withdraws phase II trial of bromfenac ophthalmic for Dry eye disease prior to enrolment (project postponed) (NCT01478555)
  • 28 Nov 2016 Launched for Ocular inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top